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Oslo, NorwayIntroduction: A minimal increase in the albumin-to-creatinine ratio (ACR) predicts cardiovascular disease
and mortality, but whether it predicts kidney function loss in nondiabetic persons is unclear. We investi-
gated the association between ACR in the optimal or high-normal range and the rate of glomerular
filtration rate (GFR) decline in a cohort from the general population without diabetes, cardiovascular, or
chronic kidney disease.
Methods: In the Renal Iohexol Clearance Survey, we measured GFR using iohexol clearance in 1567
middle-aged nondiabetic individuals with an ACR <3.40 mg/mmol (30.0 mg/g) at baseline. The ACR was
measured in unfrozen morning urine samples collected on 3 days before the GFRmeasurements. A total of
1278 (81%) participants had follow-up with GFR measurements after a median of 5.6 years.
Results: The median ACR at baseline was 0.22 mg/mmol (interquartile range: 0.100.51 mg/mmol), the
mean  SD GFR was 104.0  20.1 ml/min, and the mean  SD GFR decline rate was 0.95  2.23 ml/min
per year. Higher baseline ACR levels were associated with a steeper GFR decline in adjusted linear mixed
models. Study participants with ACR levels of 0.11 to 0.45 and 0.46  3.40 mg/mmol had a 0.25 ml/min per
year (95% confidence interval [95% CI]: 0.03 to 0.53) and 0.31 ml/min per year (95% CI: 0.020.60) steeper
rate of decline than those with ACR #0.10 mg/mmol in multivariable-adjusted analyses. Among study
participants with an ACR of <1.13 mg/mmol (defined as the optimal range), those with an ACR of 0.11 to
1.12 mg/mmol (n ¼ 812) had a 0.28 ml/min per year (95% CI: 0.040.52) steeper rate of GFR decline than
those with an ACR of #0.10 mg/mmol (n ¼ 655).
Conclusion: A mildly increased ACR is an independent risk factor for faster GFR decline in nondiabetic
individuals.
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hronic kidney disease (CKD), defined as a glomer-
ular filtration rate (GFR) <60 ml/min per 1.73 m2,
is highly prevalent and is attributed to 4% of deaths
worldwide.1 Therefore, it is important to identify
persons at high risk of an accelerated GFR decline at an
early stage. However, plasma creatinine is an insensi-
tive marker of early GFR decline and may not increase
before 30% to 40% of kidney function is lost. More-
over, clinical risk factors, such as hypertension and
prediabetes, do not predict accelerated decline in
measured GFR during approximately 6 years ofspondence: Toralf Melsom, Section of Nephrology, Univer-
ospital of North Norway, N-9038 Tromsø, Norway. E-mail:
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International Reports (2018) 3, 817–824follow-up in nondiabetic persons.2,3 Therefore, nonin-
vasive biomarkers for the prediction of GFR decline in
the general population are needed.
A urinary albumin-to-creatinine ratio (ACR) $3.40
mg/mmol (30.0 mg/g) is a marker of glomerular damage,
is included in the definition of CKD if it persist for $3
months, and is a risk factor for GFR decline.4,5 How-
ever, only a small proportion of individuals develop
albuminuria; therefore, it is not a useful biomarker for
GFR decline in most individuals in the general popu-
lation. A low-grade increase in ACR (0.60.9 mg/mmol)
is much more common and is a risk factor for cardio-
vascular disease (CVD) and all-cause mortality in the
general population.6 Previous studies of CKD risk in the
general population defined optimal ACR levels as <1.13
mg/mmol and high-normal ACR as 1.13 to 3.40 mg/
mmol.7 Whether an ACR in this range is an817
CLINICAL RESEARCH T Melsom et al.: Normal-Range ACR and GFR Declineindependent risk factor for accelerated GFR decline in
nondiabetic persons is unknown.
We studied the hypothesis that higher ACR within
the normal range is associated with a faster decline in
measured GFR in a Caucasian population without pre-
existing diabetes, CVD, or CKD.METHODS
Study Population
The Renal Iohexol Clearance Survey in Tromsø 6
(RENIS-T6) was conducted from 2007 to 2009 as a
substudy of the population-based sixth Tromsø Study
in the municipality of Tromsø, Northern Norway.8 The
RENIS-T6 included a representative sample of 1627
individuals, aged 50 to 62 years, from the general
population who did not have self-reported kidney
disease, CVD, or diabetes (Figure 1). Twenty-four
subjects had albuminuria, defined as an ACR $3.40
mg/mmol, 5 subjects had missing ACR values, and 31
subjects had diabetes (defined as fasting glucose $7.0
mmol/l, hemoglobin A1c $6.5%, or the use of antidi-
abetic medication). These 60 subjects were excluded
from the present study. Of the remaining 1567 subjects,
1278 (82%) had a follow-up measurement of GFR in the
RENIS Follow-Up study (RENIS-FU]) after a medianN = 1627
The RENIS-T6 cohort
(Baseline GFR measurement)
N = 1567 (100%)
Eligible for the RENIS Follow-Up and 
without albuminuria and diabetes.
n = 60
Albuminuria >3.40 mmol/mg 
(>30.0 mg/g) or missing ACR 
(n = 29) or diabetes (n = 31).
N = 1278 (82%)
Included in the present study with a follow-
up GFR measurement (Second GFR)
n = 87
A random sample with repeated GFR 
measurement (Third GFR)
n = 30
Dead (n = 23) or possible 
adverse reacon to iohexol 
at baseline (n = 7).
N = 1537 
Invited.
Figure 1. Inclusion of subjects. The Renal Iohexol Clearance Survey
in Tromsø 6 (RENIS-T6) and Follow-Up (RENIS-FU). ACR, albumin-to-
creatinine ratio; GFR, glomerular filtration rate.
818(interquartile range [IQR]) of 5.6 years (IQR: 5.2–6.0
years) (Figure 1). A random sample of 86 subjects had a
third GFR measurement within 2 months after the
second GFR measurement, which was necessary for the
linear mixed regression analyses, with a random
intercept and slope, and an unstructured covariance
matrix.2
There were small differences in the characteristics of
the included participants in RENIS-FU compared with
the 18% who were lost to follow-up, except for the
percentage of current smokers, which was 18% versus
28% (P < 0.01) (other significant differences were
body mass index [BMI]: 27.1 kg/m2 vs. 27.6 kg/m2, P ¼
0.04; hemoglobin A1c: 5.5% vs. 5.6%, P ¼ 0.01; and
ACR: 0.22 mg/mmol vs. 0.30 mg/mmol, P ¼ 0.02).2
The Regional Ethics Committee of Northern Norway
approved the study, and all subjects provided written
informed consent. The study adhered to the Declara-
tion of Helsinki.
Data
The RENIS-T6 and RENIS-FU studies were conducted
at the Clinical Research Unit at the University Hospital
of Northern Norway with a standardized procedure.
The participants met between 8:00 and 10:00 AM after
an overnight fast, including abstinence from tobacco.
Both visits included a health questionnaire with
questions on tobacco use, leisure time physical exer-
cise, and all current medications. Current smoking was
categorized as daily tobacco use (yes/no).
GFR was measured using single-sample plasma clear-
ance of iohexol, as described in detail elsewhere.8 All
participants were instructed to avoid large meals with
meat and nonsteroid anti-inflammatory drugs 2 days
before the investigation. Study participants with signs of
acute illness, such as respiratory or urinary infection,
were rescheduled to a later appointment. The concen-
tration of serum iohexol was measured by high-
performance liquid chromatography, as described by
Nilsson-Ehle.9 GFR was calculated as described by
Jacobsson.10 The mean coefficient of variation (95% CI)
for the intraindividual variation in GFR was 4.2%
(3.4%4.9%).3
Three samples of first-void morning spot urine were
collected on consecutive days before the GFR mea-
surements. Urinary albumin and creatinine concentra-
tions were measured in fresh urine using an ABX
PENTRA autoanalyzer (Horiba ABX) and kits from ABX
Diagnostics (Montpellier, France).11 The ACR in milli-
grams per millimoles was calculated for each urine
specimen, and the median ACR value was used in the
analyses. In samples with no detectable urinary
albumin concentration, ACR was set to 0.10 mg/mmol
(0.88 mg/g), which corresponded to the lowest ACRKidney International Reports (2018) 3, 817–824
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normal albuminuria was defined as an ACR of 1.13 to
3.40 mg/mmol (10.0–30.0 mg/g).12
Values for fasting serum glucose, triglycerides, and
cholesterol were measured on the Modular model P800
(Roche Diagnostics, Mannheim, Germany). We
measured fasting insulin levels using an enzyme-linked
immunosorbent kit (DRG Instruments, Marburg, Ger-
many)13 and high-sensitivity C-reactive protein as
previously reported.14
Office blood pressure (BP) and resting heart rate were
measured 3 times in a seated position after a 2-minute
rest.15 Ambulatory BP was measured using the Space-
lab 90207 (Spacelab Inc., Redmond, WA) from after the
GFR measurement until the next day. BP and heart rate
were measured at 20-minute intervals from 08:00 AM to
10:00 PM and at 45-minute intervals from 10:00 PM to
08:00 AM. Persons with invalid measurements had their
measurements repeated as soon as possible. The mean
daytime and nighttime systolic BP and diastolic BPs were
calculated as the weighted mean of measurements from
10:00 AM to 10.00 PM and from midnight until 06.00
AM, respectively, as previously reported.15 Subjects
with office systolic BP $140 mm Hg, diastolic BP $90
mm Hg, or who were using antihypertensive medication
were categorized as having hypertension.
Statistical Analyses
Study population characteristics are presented as the
means  SD, medians (IQR) for skewed data, or
numbers (percentages). ACR was categorized into 3
groups (no albuminuria; ACR #0.1 mg/mmol, which
corresponded to the detection limit for urinary albu-
min, and 2 equally sized groups based on low or high
ACR). A linear trend across ACR groups was tested
with analysis of variance and median regression
for continuous variables and with logistic regression
for dichotomous variables.
Fourteen missing values for ambulatory daytime BP
and heart rate were replaced by the office BP and
resting heart rate values, respectively.
The association of ACR at baseline with the GFR
change rate was analyzed in a linear mixed regression
model with a random intercept and slope, and by
including 2-way interaction terms between the ACR
variable and the time variable.16–18 All 1567 partici-
pants with 1 to 3 GFR measurements were included in
the analyses because linear mixed models allow for
missing observations at $1 timepoints.16,17 Although 3
measurements were only available for a random sub-
sample (n ¼ 87) in RENIS-FU, this sufficed for esti-
mating the 3 variance components in the unstructured
covariance matrix of the model.18 Absolute GFR in
milliliters per minute was used as the dependentKidney International Reports (2018) 3, 817–824variable. Observation time from baseline was used as
the independent time variable. The association of ACR
at baseline with rapid GFR decline (yes/no) was
analyzed using logistic regression. Rapid GFR decline
was defined as >3 ml/min per 1.73 m2 per year.19
We adjusted for the following baseline variables in 3
models: model 1 (age, sex, body weight, and height),
model 2 (model 1 plus fasting glucose, smoking status
[yes/no], ambulatory systolic BP, use of antihyperten-
sive medications, and high-sensitivity C-reactive pro-
tein), and model 3 (model 2 plus ambulatory heart rate,
fasting triglycerides, low-density lipoprotein choles-
terol, and fasting insulin). An interaction term between
these variables and the time variable was included to
adjust for each variable’s effect on the slope. We tested
for effect modification by age, sex, fasting glucose, and
BP by including an interaction term among each of
these variables, ACR, and the time variable.
Stata software version 14.1 (Stata Corp., College
Station, TX) was used for statistical analysis. Statistical
significance was set at P < 0.05.
RESULTS
Population Characteristics
The mean  SD age at baseline was 58.1 3.8 years;
mean body mass index (BMI), 27.2  4.0 kg/m2; mean
GFR, 103.8  19.9 ml/min; and the median (IQR) ACR,
0.23 mg/mmol (IQR: 0.10–0.52 mg/mmol). A total of 655
persons (42%) had an ACR #0.10 mg/mmol, which
corresponded to the detection limit for urinary albumin
concentration. This group was defined as the reference
group. The remaining participants were divided into 2
equally sized groups based on their ACRs. The popu-
lation characteristics at baseline for these 3 groups are
shown in Table 1. Higher levels of ACR was associated
with current smoking, higher BMI, higher tri-
glycerides, and higher daytime and nighttime ambu-
latory BPs. There was also a quadratic trend between
levels of ACR and GFR (Table 1).
Association Between Baseline ACR and GFR
Change Rate
The unadjusted mean  SD absolute and body surface
area adjusted GFR decline rate was0.95 2.23 ml/min
per year and0.84  2.00 ml/min per 1.73 m2 per year.
The annual GFR decline rate in milliliters per minute
was 0.79 (95% confidence interval [CI]: 0.97
to 0.62), 1.03 (1.23 to 0.82), and 1.15 (1.38
to 0.92) for the 3 ACR groups, respectively. A higher
ACR was associated with a steeper GFR decline in 3
different multivariable-adjusted linear mixed models
(Table 2). We obtained similar results when urinary al-
bumin levels were not corrected for urinary creatinine
(Table 2), when we used the mean ACR instead of the819










(n [ 456) P value for linear trend
Urinary ACR, mg/mmol < 0.1 0.29 (0.20.36) 0.76 (0.571.07)
Male sex, n (%) 291 (44) 273 (60) 202 (44) 0.97b
Age, yr 58.0  3.8 57.8  3.9 58.3  3.7 0.37
Body mass index, kg/m2 27.0  3.9 27.2  3.6 27.6  4.3 0.02
Current smoker, 118 (18) 89 (20) 108 (24) 0.02
Office SBP, mm Hg 126.9  16.6 129.7  16.8 132.4  19.1 <0.001
Office DBP, mm Hg 82.1  9.3 84.0  9.6 84.2  10.2 <0.001
Resting heart rate, beats/min 66.6  9.8 65.5  10.1 67.4  9.5 0.18b
Hypertension 220 (34) 193 (42) 214 (47) <0.001
Antihypertensive med., n (%) 105 (16) 82 (18) 91 (20) 0.09
Ambulatory BP measurements, mm Hg
Daytime SBP 127.8  11.9 130.3  2.9 132.7  14.2 <0.001
Daytime DBP 80.7  7.9 82.8  8.6 83.2  9.4 <0.001
Nighttime SBP 108.9  11.0 110.8  12.4 113.4  13.1 <0.001
Nighttime DBP 65.1  7.6 66.9  8.3 67.5 9.2 <0.001
LDL cholesterol, mmol/l 3.66  0.84 3.69  0.86 3.65  0.88 0.83
HDL cholesterol, mmol/l 1.57  0.40 1.48  0.42 1.54  0.44 0.18b
Fasting triglycerides, mmol/l 1.0 (0.71.3) 1.0 (0.81.5) 1.1 (0.81.5) 0.002
Fasting glucose, mmol/l 5.3 (5.05.6) 5.3 (5.05.6) 5.30 (5.05.6) 1.00
Fasting insulin 8.3 (6.112.0) 8.4 (6.012.0) 8.73 (6.112.9) 0.12
High-sensitivity CRP 2.36  4.73 2.14  3.52 3.11  10.86 0.08
Absolute GFR, ml/min 102.0  19.7 106.0  19.2 104.2  20.7 0.07b
GFR, ml/min per 1.73 m2 93.1  14.3 94.8  13.9 94.0  14.7 0.29
ACR, albumin-to-creatinine ratio; BP, blood pressure; CRP, C-reactive protein; DBP, diastolic BP; GFR, glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipo-
protein; RENIS-FU Study, the Renal Iohexol-clearance Survey Follow-up Study; SBP, systolic BP.
Estimates are given as mean  SD, median (interquartile range), or no. (%).
aParticipants without albuminuria (ACR <3.4 mg/mmol (30 mg/g)) and diabetes at baseline.
bP < 0.05 for quadratic trend.
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each person collected on separate days at baseline), after
adjusting for ambulatory diastolic BP instead of systolic
BP, and after additional adjustment for change in anti-
hypertensive medications from baseline to follow-up
(not shown). We also repeated the analyses using body
surface area adjusted GFR (milliliters per minute per 1.73
m2) instead of absolute GFR as the dependent variable.
The results were essentially the same as shown in
Supplementary Table S1.
In the subgroup of study participants with an
ACR<1.13 (n¼ 1467), those with an ACR of 0.11 to 1.12
(n¼ 812) had a 0.28ml/min per year (95%CI: 0.040.52)
steeper rate ofGFRdecline than thosewith anACR#0.10
mg/mmol (n ¼ 655) in the fully adjusted model.
No interaction was found for age, sex, fasting
glucose, BP, or hypertension (P $ 0.05). However,
there was a tendency toward a slightly stronger effect
of the ACR on the GFR decline rate in the 940 persons
without hypertension at baseline (Table 2 and
Figure 2). In the subgroup of study participants with
no hypertension, those with an ACR >0.10 mg/mmol
had a 1.89 ml/min (95% CI: 0.10–3.68) higher baseline
GFR and a 0.45 ml/min per year (95% CI: 0.18–0.73)
steeper GFR decline rate compared with persons with
no albuminuria, in the fully adjusted model (Figure 2).820One hundred twenty-eight participants had rapid
GFR decline defined as an annual decline rate >3.0 ml/
min per 1.73 m2. The odds ratio of rapid decline was
1.17 (95% CI: 0.97–1.42) per SD increase baseline ACR
in the model adjusted for age, sex, height, and weight,
and 1.10 (95% CI: 0.90–1.35) in the fully adjusted
model (as model 3, Table 2).DISCUSSION
In a cohort representative of the general population
without diabetes, CKD or CVD, we found that mildly
increased ACR within the optimal or high-normal7
range at baseline was independently associated with a
steeper decline in measured GFR. Individuals with ACR
between 0.11 and 0.45 mg/mmol and 0.46 and 3.40
mg/mmol had on average 0.25 ml/min per year (95%
CI: –0.03 to 0.53) and 0.31 (95% CI: 0.02–0.60) steeper
decline rates compared with those with no albumin-
uria, which was a moderate difference considering the
average decline rate of 0.95 ml/min per year in this
nondiabetic population.
Several large population studies have confirmed that
an ACR $3.40 mg/mmol (30.0 mg/g) predicts GFR
decline and progression of CKD.5,20 This has motivated
the inclusion of ACR $3.40 mg/mmol in CKD staging.4Kidney International Reports (2018) 3, 817–824
Table 2. The associations between baseline ACR and GFR change rates in separate linear mixed regression analyses
Baseline ACR levels
Model 1 Model 2 Model 3
ml/min
per yeara (95% CI) P value
ml/min
per yeara (95% CI) P value
ml/min
per yeara (95% CI) P value
All study participantsb
Urinary log albumin, per SD (n ¼ 1567) 0.18 (0.30 to0.06) 0.00 0.16 (0.28 to 0.03) 0.01 0.14 (0.26 to 0.02) 0.02
Urinary 1/creatinine, per SD (n ¼ 1567) 0.10 (0.03 to 0.24) 0.14 0.08 (0.06 to 0.21) 0.27 0.07 (0.07 to 0.20) 0.34
Urinary log ACR, per SD (n ¼ 1567) 0.14 (0.25 to 0.02) 0.02 0.13 (0.24 to 0.01) 0.04 0.11 (0.23 to 0.01) 0.06
ACR #0.10 mg/mmol (n ¼ 655) Ref Ref Ref
ACR 0.110.45 mg/mmol (n ¼ 456) 0.24 (0.53 to 0.04) 0.09 0.24 (0.52 to 0.05) 0.10 0.25 (0.53 to 0.03) 0.08
ACR 0.463.40 mg/mmol (n ¼ 456) 0.35 (0.63 to 0.06) 0.02 0.33 (0.62 to 0.04) 0.02 0.31 (0.60 to 0.02) 0.03
Persons without hypertensionc
Log ACR, per SD increase (n ¼ 940) 0.21 (0.37 to 0.05) 0.01 0.20 (0.36 to 0.04) 0.02 0.19 (0.35 to 0.03) 0.02
ACR #0.10 mg/mmol (n ¼ 435) Ref Ref Ref
ACR 0.110.45 mg/mmol (n ¼ 263) 0.39 (0.72 to 0.06) 0.02 0.42 (0.75 to 0.09) 0.01 0.42 (0.74 to 0.09) 0.01
ACR 0.463.40 mg/mmol (n ¼ 242) 0.49 (0.83 to 0.15) <0.01 0.47 (0.81 to 0.13) <0.01 0.46 (0.80 to 0.11) <0.01
ACR, albumin-to-creatinine ratio; GFR, glomerular filtration rate.
Model 1: Adjusted for sex and age, height, and weight at baseline.
Model 2: As in Model 1 and adjusted for ambulatory systolic blood pressure (BP), fasting glucose, current smoking, high-sensitivity C-reactive protein, and the use of antihypertensive
medications.
Model 3: As in Model 2 and adjusted for ambulatory heart rate, low-density lipoprotein cholesterol, triglycerides, and fasting insulin.
aA negative coefficient means a steeper decline.
bIncludes persons without diabetes, and ACR <3.40 mmol/mg (30.0 mg/g) in the Renal Iohexol Clearance Survey in Tromso 6 (RENIS-T6).
cA total of 627 persons with hypertension were defined as having office systolic BP $140 mm Hg, diastolic BP $ 90 mm Hg, or the use of antihypertensive medications were excluded.
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disease and not only a more general marker of endo-
thelial dysfunction has been debated. No previous
study has assessed the independent association
between ACR within the normal range and measured
GFR decline in the general nondiabetic population.
Three previous publications from the population-
based Prevention of Renal and Vascular End-Stage
Disease (PREVEND) study reported that urinary albu-
min excretion (UAE) levels $15 mg/24 h (approxi-
mately corresponding to an ACR $1.13 mmol/l [$10.0
mg/g]) predicted a decline in eGFR and incident
CKD.21–23 However, these studies did not exclude
participants with albuminuria defined as ACR $3.40
mmol/l ($30.0 mg/g) from their analyses, and 2 of them
did not adjust for common clinical risk factors. In the
third study, Halbesma et al. found that UAE levels in
this range predicted eGFR decline in men, but not in
women, after multivariable adjustment.23 In contrast,
we did not observe any effect modification by sex in
our study using measured GFR, although the ACR
levels were lower than those in the PREVEND study. A
few other studies of the general population found an
association between ACR and accelerated decline in
eGFR, but these studies did not exclude individuals
with diabetes and/or albuminuria at baseline.24,25
Age-related decline in GFR is an important cause of
the high prevalence of CKD. Individuals who develop a
moderately reduced eGFR (<45 ml/min per 1.73 m2) at
the age of 55 to 74 years have an approximately 60% to
200% and 400% to 600% increased risk of death and
end-stage renal disease (ESRD) versus those with esti-
mated GFR of 80 ml/min per 1.73 m2, respectively.26Kidney International Reports (2018) 3, 817–824Different screening strategies to detect CKD have
therefore been proposed, either of high-risk groups
such as individuals with diabetes or of the general
population aged older than 55 years.22,27–30 However,
existing risk models may have better discriminating
abilities in high-risk compared with low-risk pop-
ulations and for outcomes such as ESRD compared with
early GFR decline or incident CKD.31–34 Our study
indicated that even slightly higher ACR levels than
normal might be an important risk factor for GFR
decline in middle-aged nondiabetic individuals inde-
pendent of common risk factors for CKD. It should be
noted that most participants in this study had a GFR
within the normal range at follow-up, and thus we
could not determine whether those with accelerated
GFR decline progressed to CKD. However, in another
population-based study, Hallan et al. found an
increased risk of ESRD with a higher ACR that
continued into the normo-albuminuria range, although
that study included persons with diabetes, CKD, and
CVD at baseline.20
Larger population-based studies with longer follow-
up periods should evaluate the effect of screening for
albuminuria below the currently accepted thresholds.
Treatment that reduces the ACR, such as the use of
angiotensin-converting enzyme inhibitors, has been
shown to reduce the long-term GFR decline and risk of
ESRD in patientswith diabetes and hypertension.35–37 To
our knowledge, no randomized intervention trials have
investigated the effects of reducing low-grade albumin-
uria in people without diabetes, CKD, or hypertension.
We observed a quadratic trend between baseline
GFR and ACR levels in the total cohort and a higher821
Figure 2. Adjusted glomerular filtration rate (GFR) slopes for nonhypertensive persons according to albumin-to-creatinine ratio (ACR) levels.
Marginal effects on GFR levels analyzed in mixed linear regression with random intercept and slope, after adjusting for sex and baseline age,
height, weight, fasting glucose, smoking status (yes/no), ambulatory systolic blood pressure and heart rate, use of antihypertensive medications,
high-sensitivity C-reactive protein, fasting triglycerides, low-density lipoprotein cholesterol, and fasting insulin levels. Persons with hypertension
excluded. Ntotal ¼ 940; 435 with no albuminuria and 505 with an ACR of 0.11 to 3.40 mg/mmol (0.89–30.0 mg/dl). The latter group had a 0.45 ml/min
per year (95% confidence interval: 0.18–0.73) steeper GFR decline rate.
CLINICAL RESEARCH T Melsom et al.: Normal-Range ACR and GFR Declinebaseline GFR in persons with albuminuria in the sub-
group with no hypertension (Table 1 and Figure 2).
This was consistent with several previous reports.
Higher urinary albumin levels were associated with
both lower and higher GFR in cross-sectional studies,
not only in patients with diabetes,38 but also in studies
of the general population.39,40 Moreover, Halbesma
et al. found a nonlinear association between UAE levels
and change in GFR in a longitudinal study of the
general population.23 Similarly, we reported that ACR
might increase in parallel with increasing GFR in per-
sons with prediabetes during 5.6 years of follow-up,
possibly indicating an association with hyper-
filtration.3 In this study, we demonstrated that even
lower levels of ACR at baseline are associated with a
steeper GFR decline.
The major strength of this study was the use of
measured instead of estimated GFR. The estimated
GFR lacks precision in the near-normal range and is
biased by non-GFRrelated factors such as muscle
wasting, particularly in older adults. RENIS-FU is the
only longitudinal study with repeated measurements
of GFR in a representative sample of the general
population. Urine was collected from morning sam-
ples on 3 separate days, and albumin and creatinine
were assessed in unfrozen specimens. Our results
were not dependent on adjustment for urinary
creatinine, which is important because the inclusion822of urinary creatinine in the ACR might cause bias due
to the association with muscle mass (creatinine
production).
In contrast to most previous studies, we adjusted for
several potential confounders, such as high-sensitivity
C-reactive protein, fasting insulin levels, 24-hour
ambulatory BP measurement, and use of antihyper-
tensive medication, including angiotensin-converting
enzyme inhibitors and angiotensin receptor blockers.
Notably, a recent study from the CKD biomarker con-
sortium found strong associations of several tubular
biomarkers with GFR decline in unadjusted analyses,
but these associations were not significant in multi-
variable adjusted models.32
This study also had limitations. Only middle-aged
Caucasian individuals participated, which limited the
generalizability to other groups. Due to the observa-
tional design, we could not draw conclusions about a
causal connection between an ACR in this lower range
and the rate of GFR decline.
We concluded that a higher ACR within the normal
range is associated with a steeper GFR decline in
nondiabetic, middle-aged individuals from the general
population.DISCLOSURE
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